Risk Factors and Outcomes of Recurrent Candidemia in Children: Relapse or Re-Infection?
- PMID: 30654524
- PMCID: PMC6352033
- DOI: 10.3390/jcm8010099
Risk Factors and Outcomes of Recurrent Candidemia in Children: Relapse or Re-Infection?
Abstract
In this paper, our aim was to investigate the incidence, clinical characteristics, risk factors, and outcomes of recurrent candidemia in children. We retrospectively reviewed all children with candidemia from a medical center in Taiwan between 2004 and 2015. Two episodes of candidemia ≥30 days apart with clinical and microbiological resolution in the interim were defined as "late recurrence", and those that had 8⁻29 days apart from previous episodes were defined as "early recurrence". 45 patients (17.2%) had 57 episodes of recurrent candidemia, and 24 had 28 episodes of late recurrent candidemia. The median time between recurrences was 1.8 months (range: <1 month to 13 months). Of those, 29 had relapsed candidemia and 28 were re-infected by different Candida species (n = 24) or by different strains (n = 4). Recurrent candidemia patients were more likely to require echinocandins treatment, had a longer duration of candidemia, and higher rate of treatment failure (p = 0.001, 0.014, and 0.012, respectively). Underlying gastrointestinal diseases (Odds ratio (OR) 3.84; 95% Confidence interval (CI) 1.81⁻8.12) and neurological sequelae (OR 2.32; 95% CI 1.15⁻4.69) were independently associated with the development of recurrent candidemia. 17.2% of pediatric patients with candidemia developed recurrent candidemia, and approximately half were re-infected. Underlying gastrointestinal diseases and neurological sequelae were the independent risk factors for recurrent candidemia.
Keywords: antifungal resistance; late-onset sepsis; premature infants; recurrent candidemia.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Fernadez-Ruiz M., Guinea J., Lora-Pablos D., Zaragoza O., Puig-Asensio M., Almirante B., Cuenca-Estrella M., Aguado J.M. Impact of fluconazole susceptibility on the outcome of patients with candidemia: Data from a population-based surveillance. Clin. Microbiol. Infect. 2017;23:672. - PubMed
-
- Montravers P., Perrigault P.F., Timsit J.F., Mira J.P., Lortholary O., Leroy O., Gangneux J.P., Guillemot D., Bensoussan C., Bailly S., et al. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand, a prospective cohort study in French intensive care units. Clin. Microbiol. Infect. 2017;23:117. doi: 10.1016/j.cmi.2016.10.001. - DOI - PubMed
-
- Hesstvedt L., Gaustad P., Andersen C.T., Haarr E., Hannula R., Haukland H.H., Hermansen N.O., Larssen K.W., Mylvaganam H., Ranheim T.E., et al. Twenty-two years of candidaemia surveillance: Results from a Norwegian national study. Clin. Microbiol. Infect. 2015;21:938–945. doi: 10.1016/j.cmi.2015.06.008. - DOI - PubMed
-
- Tsai M.H., Wang S.H., Hsu J.F., Lin L.C., Chu S.M., Huang H.R., Chiang M.C., Fu R.H., Lu J.J., Huang Y.C. Clinical and molecular characteristics of bloodstream infections caused by Candida albicans in children from 2003 to 2011. Clin. Microbiol. Infect. 2015;21:1018. doi: 10.1016/j.cmi.2015.06.024. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources